logo

CBIO

Crescent·NASDAQ
--
--(--)
--
--(--)
2.86 / 10
Underperform

CBIO's fundamental metrics are subdued: Profit-MV and Cash-MV show moderate strength, but Asset-MV is weak and Net profit/Total profit (%) is suboptimal at 100.0%, leading to an overall Underperform rating. Historical backtests indicate limited upside potential, with one-month returns ranging from -0.54% to 7.79% across key factors.

Fundamental(2.86)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight13.04%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight11.46%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-1.01%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight19.52%
1M Return7.79%
PB-ROE
Value4.50
Score2/3
Weight27.40%
1M Return10.68%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.28%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.66%
1M Return0.86%
Asset-MV
Value-0.50
Score0/3
Weight6.67%
1M Return2.94%
Cash-MV
Value-0.07
Score2/3
Weight19.55%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.58%
1M Return-0.30%
Is CBIO undervalued or overvalued?
  • CBIO scores 2.86/10 on fundamentals and holds a Premium valuation at present. Backed by its -117.05% ROE, 0.00% net margin, -2.71 P/E ratio, 2.25 P/B ratio, and -259.60% earnings growth, these metrics solidify its Underperform investment rating.